Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.
August 27, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience and maintained a $14 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a $14 price target by a reputable analyst suggests a positive outlook for Skye Bioscience. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100